A celery seed extract compound, celery seed extract, its preparation method and application

Quercetin-3-O-[6''-O-(α-L-rhamnopyranosyl)succinoyl]-β-D-glucopyranoside was extracted from celery seeds by controlling specific pH values ​​and using macroporous adsorption resin technology. This solved the problem of incomplete research on the components of celery seed extract and achieved a highly effective effect in relieving gout and hyperuricemia.

CN123106793APending Publication Date: 2026-11-17BEIJING GUOKE HERBAL HEALTH TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611054687.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing research on the components of celery seed extract is incomplete, lacking effective methods for component screening and purification, making it difficult to fully realize its effects in lowering blood pressure, lowering blood lipids, relieving rheumatoid arthritis, gout, and hyperuricemia.

Method used

Quercetin-3-O-[6''-O-(α-L-rhamnosylpyranosyl)succinyl]-β-D-glucopyranoside was extracted from celery seeds using specific pH control and macroporous adsorption resin technology. High-purity celery seed extract was prepared by reflux extraction with ethanol-water solution, extraction with petroleum ether and ethyl acetate, and elution with AB-8 macroporous adsorption resin.

Benefits of technology

The prepared celery seed extract has the effect of inhibiting xanthine oxidase and xanthine dehydrogenase, scavenging superoxide anions, and has antioxidant and protein denaturation inhibition properties, effectively relieving gout and hyperuricemia symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106793A_ABST
    Figure CN123106793A_ABST
Patent Text Reader

Abstract

This invention provides a celery seed extract compound, a celery seed extract, its preparation method, and its applications. The inventors screened and purified the celery seed extract compound shown in Formula I, which exhibits inhibitory effects on xanthine oxidase (XO) and xanthine dehydrogenase, and also has a scavenging effect on superoxide anions. It possesses antioxidant and protein denaturation-inhibiting effects, which are beneficial for inhibiting uric acid crystallization and relieving gout and hyperuricemia. Celery seed extracts containing more than 0.5% by mass of the celery seed extract compound shown in Formula I also possess the corresponding effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to carbocyclic compounds, specifically carbocyclic compounds extracted from natural plants, and more specifically to a celery seed extract compound, a celery seed extract, its preparation method, and its applications. Background Technology

[0002] Studies have shown that celery seeds contain coumarin compounds such as umbelliferone, xanthocyanin, bergamot lactone, 5,8-dimethoxy-6,7-furanocoumarin, 6-methoxy-7-hydroxycoumarin, and isopicinol; and flavonoid compounds such as apigenin, luteolin-3C-O-β-D-glucoside, luteolin-7-O-β-D-glucoside, geraniol-7-O-β-D-glucoside, apigenin, stigmasterol-3-O-β-D-glucoside, apigenin, and apigenin glycoside.

[0003] Celery seeds contain 50 times more antihypertensive and lipid-lowering components than celery itself. Short-term use can lower blood pressure and blood lipids, and long-term use is far superior to other Chinese and Western medicines, with no toxic side effects. Celery seeds have the effect of lowering blood pressure and blood lipids, and can relieve symptoms of rheumatism, rheumatoid arthritis, gout, and hyperuricemia. However, current research on the components of celery seed extract needs further improvement. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of the existing technology and provide a celery seed extract compound, a celery seed extract, its preparation method and application.

[0005] To achieve the above objectives, the technical solution adopted by the present invention is as follows: a celery seed extract compound, wherein the chemical structural formula I of the celery seed extract compound is shown:

[0006] Formula I.

[0007] Celery seeds contain a complex array of active ingredients, offering relief for conditions such as rheumatism, arthritis, gout, and hyperuricemia. Through research and purification, the inventors obtained a celery seed extract compound as shown in Formula I, named quercetin-3-O-[6''-O-(α-L-rhamnopyranosyl)succinyl]-β-D-glucopyranoside. Studies have shown that this celery seed extract compound, as shown in Formula I, inhibits xanthine oxidase (XO) and xanthine dehydrogenase, and also scavenges superoxide anions. It possesses antioxidant and protein denaturation-inhibiting properties, which helps inhibit uric acid crystallization and alleviates gout and hyperuricemia.

[0008] The present invention also provides a celery seed extract, wherein the celery seed extract contains more than 0.5% by mass of the compound as described in claim 1.

[0009] The celery seed extract described above contains compounds as described in Formula I, which have the effect of inhibiting xanthine oxidase (XO) and xanthine dehydrogenase, and also have the effect of scavenging superoxide anions. It has antioxidant and protein denaturation inhibitory effects, which are beneficial for inhibiting uric acid crystallization and can relieve gout and hyperuricemia.

[0010] This invention also provides a method for preparing celery seed extract, the method comprising the following steps:

[0011] (1) Mix dried celery seed powder with 50%~80% ethanol aqueous solution (v / v), adjust the pH to 4.5~5.5, and reflux at 50~65℃ for extraction. During the extraction process, control the pH to 4.5~5.5. Concentrate the extract until there is no alcohol taste to obtain concentrated solution or concentrated extract.

[0012] (2) Dilute the concentrated solution or concentrated extract with water to a solid content of 7-15% (w / v) and adjust the pH to 4.5-5.5;

[0013] (3) Extracted sequentially with petroleum ether and ethyl acetate, the organic phase was removed and the aqueous phase was retained, resulting in a crude enrichment solution containing the compound as described in claim 1;

[0014] (4) After the crude enrichment liquid from step (3) is concentrated under reduced pressure, it is dried at a temperature not higher than 25°C and then powdered to obtain celery seed extract.

[0015] The celery seed extract prepared by the above method contains the compound described in Formula I, which has the effect of inhibiting xanthine oxidase (XO) and xanthine dehydrogenase, and also has the effect of scavenging superoxide anions. It has antioxidant and protein denaturation inhibition effects, which are beneficial to inhibiting uric acid crystallization and can relieve gout and hyperuricemia.

[0016] Preferably, in step (1), the material-to-liquid ratio is 1:(10~20)g / mL, and the reflux extraction time is 1~3 hours.

[0017] Preferably, in step (1), the pH is adjusted to 4.8~5.2, and in step (2), the pH is adjusted to 4.8~5.2.

[0018] The inventors discovered that, with other parameters remaining the same, controlling the pH during the extraction process to 4.8-5.2 can increase the content of the compounds described in Formula I in the extract. Those skilled in the art will also understand that the pH adjustment in steps (1) and (2) is to control the pH of the entire aqueous phase to 4.8-5.2 in steps (1) and (2), and real-time pH control can also be achieved.

[0019] Preferably, the preparation method further includes the following steps after step (3) and before step (4): the pretreated AB-8 macroporous adsorption resin adsorbs the crude enrichment liquid, and the volume ratio of the pretreated AB-8 macroporous adsorption resin to the crude enrichment liquid is 1:(1~3); the AB-8 macroporous adsorption resin is separated by eluting the AB-8 macroporous adsorption resin with a 20%~80% gradient ethanol aqueous solution, the ethanol volume of the 20%~80% gradient ethanol aqueous solution gradually increases with the elution sequence, and the elution fraction of the 50%~80% gradient ethanol aqueous solution is collected;

[0020] Celery seed extract was obtained by concentration under reduced pressure, drying at a temperature not exceeding 25°C, and then grinding into powder.

[0021] Preferably, the preparation method uses AB-8 type macroporous adsorption resin column packing and elution in the steps after step (3) and before step (4).

[0022] This invention also provides a method for preparing compounds extracted from celery seeds, the method comprising the following steps:

[0023] (1) Mix dried celery seed powder with 50%~80% ethanol aqueous solution (v / v), adjust the pH to 4.5~5.5, and reflux at 50~65℃ for extraction. During the extraction process, control the pH to 4.5~5.5. Concentrate the extract until there is no alcohol taste to obtain concentrated solution or concentrated extract.

[0024] (2) Dilute the concentrated solution or concentrated extract with water to a solid content of 7-15% (w / v) and adjust the pH to 4.5-5.5;

[0025] (3) Extracted sequentially with petroleum ether and ethyl acetate, the organic phase was removed and the aqueous phase was retained, resulting in a crude enrichment solution containing the compound as described in claim 1;

[0026] (4) AB-8 macroporous adsorption resin pre-soaked in 95% or more ethanol was packed into a column. After loading 1 to 3 column volumes of coarse enrichment solution onto the column, it was eluted with 2.5 to 5 column volumes of water.

[0027] (5) Elute the AB-8 type macroporous adsorption resin column with a gradient ethanol aqueous solution of 20%~80%. The ethanol volume of the gradient ethanol aqueous solution of 20%~80% gradually increases with the elution sequence. Collect the elution fraction of the gradient ethanol aqueous solution of 50%~80%, concentrate under reduced pressure, and dry at a temperature not higher than 25℃ to obtain celery seed extract.

[0028] (6) The celery seed extract from step (5) is dissolved in 45%~55% methanol / water (v / v) to prepare a solution with a concentration of 10~50 mg / mL. After filtration through an organic filter membrane, the solution is introduced into a reversed-phase preparative chromatography-mass spectrometry instrument. The fraction with UV monitoring at 340~360 nm and mass spectra that meet the [MH]=709.18 is the fraction of the celery seed extract compound as described in Formula I.

[0029] Those skilled in the art will understand that [MH] = 709.18 is the mass-to-nucleus ratio of the compound described in Formula I under negative ionization mode. Based on this, the fractions in the mass spectrometer within a reasonable error range of [MH] = 709.18 are all compounds described in Formula I. Of course, those skilled in the art will also understand that in a certain extraction and preparation chromatography, the mass-to-nucleus ratio of the fraction of the compound described in Formula I is unique. Under the premise of instrument calibration, those skilled in the art can find the response signal of the fraction of the compound described in Formula I within a reasonable error range of [MH] = 709.18. After multiple preparation chromatographys, the purification of the target compound can be achieved.

[0030] Preferably, in step (1), the material-to-liquid ratio is 1:(10~20)g / mL, and the reflux extraction time is 1~3 hours.

[0031] Preferably, in step (1), the pH is adjusted to 4.8~5.2, and in step (2), the pH is adjusted to 4.8~5.2.

[0032] The present invention also provides the application of the celery seed extract compound as described in Formula I in the preparation of health products for relieving hyperuricemia.

[0033] The present invention also provides the use of the celery seed extract containing the celery seed extract compound as described in Formula I in the preparation of health products for relieving hyperuricemia.

[0034] The beneficial effects of this invention are as follows: This invention provides a celery seed extract compound, a celery seed extract, its preparation method, and its application. The celery seed extract compound, as shown in Formula I, is extracted and purified from celery seeds and named quercetin-3-O-[6''-O-(α-L-rhamnopyranosyl)succinyl]-β-D-glucopyranoside. The celery seed extract compound shown in Formula I of this invention has the effect of inhibiting xanthine oxidase (XO) and xanthine dehydrogenase, and also has a scavenging effect on superoxide anions. It has antioxidant and protein denaturation inhibitory effects, which are beneficial for inhibiting uric acid crystallization and relieving gout and hyperuricemia. The celery seed extract provided by this invention has the same effects as described above. Attached Figure Description

[0035] Figure 1 This is a chromatogram of the celery seed extract of the present invention.

[0036] Figure 2 This is the 1H NMR spectrum of the celery seed extract compound of this invention.

[0037] Figure 3 This is the carbon NMR spectrum of the celery seed extract compound of this invention, wherein, Figure 3 (b) Figure 3 (c) are magnified views of local displacements in the ranges of 130~100ppm and 100~60ppm, respectively.

[0038] Figure 4 This is a schematic diagram of the chemical structure of the celery seed extract compound of the present invention. Detailed Implementation

[0039] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0040] Example 1

[0041] As an embodiment of the present invention, a celery seed extract compound has the following chemical structural formula I:

[0042] Formula I.

[0043] Example 2

[0044] As an embodiment of the present invention, the method for preparing celery seed extract compounds includes the following steps:

[0045] (1) Mix dried celery seed powder with 50%~80% ethanol aqueous solution (v / v), adjust the pH to 4.5~5.5, and reflux extract at 50~65℃. During the extraction process, control the pH to 4.5~5.5. Concentrate the extract until there is no alcohol smell to obtain concentrated solution or concentrated extract. The material-liquid ratio is 1:(10~20)g / mL, and the reflux extraction time is 1~3 hours.

[0046] (2) Dilute the concentrated solution or concentrated extract with water to a solid content of 7-15% (w / v) and adjust the pH to 4.5-5.5;

[0047] (3) Extracted sequentially with petroleum ether and ethyl acetate, the organic phase was removed and the aqueous phase was retained, resulting in a crude enrichment solution containing the compound as described in claim 1;

[0048] (4) AB-8 macroporous adsorption resin pre-soaked in 95% or more ethanol was packed into a column. After loading 1 to 3 column volumes of coarse enrichment solution onto the column, it was eluted with 2.5 to 5 column volumes of water.

[0049] (5) Elute the AB-8 type macroporous adsorption resin column with a gradient ethanol aqueous solution of 20%~80%. The ethanol volume of the gradient ethanol aqueous solution of 20%~80% gradually increases with the elution sequence. Collect the elution fraction of the gradient ethanol aqueous solution of 50%~80%, concentrate under reduced pressure, and dry at a temperature not higher than 25℃ to obtain celery seed extract.

[0050] (6) The celery seed extract from step (5) is dissolved in 45%~55% methanol / water (v / v) to prepare a solution with a concentration of 10~50 mg / mL. After filtration through an organic filter membrane, the solution is introduced into a reversed-phase preparative chromatography-mass spectrometry instrument. The fraction with UV monitoring at 340~360 nm and mass spectra that meet the [MH]=709.18 is the fraction of the celery seed extract compound with the chemical structure of Formula I.

[0051] Within the parameter range of the above embodiments, the key is to control the pH of steps (1) and (2) within the range of 4.5 to 5.5. A purified fraction of the celery seed extract compound with the chemical structure of Formula I can be obtained by UV monitoring at 340 to 360 nm and mass spectrometry conforming to [MH] = 709.18. Other parameters besides pH affect the content of the celery seed extract compound with the chemical structure of Formula I in the celery seed extract.

[0052] Example 3

[0053] The present invention also provides a celery seed extract containing more than 0.5% by mass of a celery seed extract compound of formula I.

[0054] Example 4

[0055] As an embodiment of the present invention, the method for preparing celery seed extract includes the following steps:

[0056] (1) Mix dried celery seed powder with 65% ethanol aqueous solution (v / v), adjust pH to 5.0, and reflux extract at 55℃ for 2 hours. During the extraction, control pH at 5.0. Test pH every 20 minutes during extraction and control pH in the range of 4.8~5.2. After extraction, concentrate the extract until there is no alcohol smell to obtain concentrated solution or concentrated extract; the material-liquid ratio is 1:15g / mL.

[0057] (2) Dilute the concentrated solution or concentrated extract with water to a solid content of 10% (w / v) and adjust the pH to 5.0;

[0058] (3) Extracted sequentially with petroleum ether and ethyl acetate by volume, the organic phase was removed and the aqueous phase was retained, resulting in a crude enrichment solution of the compound with the chemical structure as described in Formula I;

[0059] (4) AB-8 macroporous adsorption resin was pre-soaked in 95% ethanol aqueous solution for 24 hours and then loaded onto the column. After loading the column with 2 column volumes of coarse enrichment solution, it was eluted with 3 column volumes of water.

[0060] (5) Elute the AB-8 macroporous adsorption resin column with two volumes of gradient ethanol aqueous solution of 20%, 40%, 50%, 65% and 80% respectively. Collect the elution fraction of 50%~80% gradient ethanol aqueous solution, concentrate under reduced pressure, and dry under vacuum at 20°C to obtain celery seed extract.

[0061] Chromatographic analysis revealed that the dried extract of the elution fraction from a 50%–80% gradient ethanol aqueous solution contained 0.76% of a compound with the chemical structure described in Formula I.

[0062] Experimental methods

[0063] I. Preparation of Extracts

[0064] Celery seeds, with their skins on, are crushed and then passed through a 40-mesh sieve.

[0065] (1) Mix dried celery seed powder with 65% ethanol aqueous solution (v / v), adjust the pH to 5.0, and reflux at 55℃ for 2 hours. During the extraction process, control the pH at 5.0. Test the pH every 20 minutes during the extraction. If the pH deviates from the range of 4.8~5.2, adjust the pH to 5.0. After the extraction is completed, concentrate the extract until there is no alcohol smell to obtain concentrated solution or concentrated extract; the material-liquid ratio is 1:15g / mL.

[0066] (2) Dilute the concentrated solution or concentrated extract with water to a solid content of 10% (w / v) and adjust the pH to 5.0;

[0067] (3) Extracted sequentially with petroleum ether and ethyl acetate by volume, the organic phase was removed and the aqueous phase was retained, resulting in a crude enrichment solution of the compound with the chemical structure as described in Formula I;

[0068] (4) AB-8 macroporous adsorption resin was pre-soaked in 95% ethanol aqueous solution for 24 hours and then loaded onto the column. After loading the column with 2 column volumes of coarse enrichment solution, it was eluted with 3 column volumes of water.

[0069] (5) Elute the AB-8 macroporous adsorption resin column with two volumes of gradient ethanol aqueous solution of 20%, 40%, 50%, 65% and 80% respectively. Collect the elution fraction of 50%~80% gradient ethanol aqueous solution, concentrate under reduced pressure, and dry under vacuum at 20°C to obtain celery seed extract.

[0070] II. Characterization of Celery Seed Extract by Chromatography-Mass Spectrometry

[0071] (I) Sample Preparation

[0072] Take 100 mg of celery seed extract obtained by vacuum drying at 20℃, add 0.1% (mass) formic acid-methanol (50% volume)-water (50% volume) solution, and adjust the pH to 5.0 with triethylamine as the solvent to dissolve the celery seed extract.

[0073] Dissolve celery seed extract by vortexing for 5 min, sonicating for 30 min, and filtering through a 0.22 μm organic filter membrane. Inject the diluted solution.

[0074] Injection concentration: 0.2 μg / mL.

[0075] (II) Chromatography-Mass Spectrometry Detection Method

[0076] 1. Chromatographic conditions

[0077] Chromatographic column: Waters Acquity UPLC BEH C18 (2.1×100 mm, 1.7 μm), column temperature: 35℃, injection volume: 2 μL, flow rate: 0.3 mL / min, mobile phase: A: 0.1% formic acid-water (v / v), B: 0.1% formic acid-acetonitrile (v / v).

[0078] The gradient elution procedure is shown in Table 1.

[0079] Table 1 Gradient elution program

[0080] 2. Ultraviolet (UV) detector

[0081] Ultraviolet scanning wavelength range: 200~380 nm

[0082] 3. Mass spectrometry conditions

[0083] (1) Ion source

[0084] Ion source: Electrospray ionization (ESI) source

[0085] Scanning mode: Negative ion collection

[0086] Capillary voltage: ESI - 3.0 kV

[0087] Ion source temperature: 120℃

[0088] Desolvation gas (N2) temperature: 350℃

[0089] Desolventizing gas flow rate: 800 L / h

[0090] Conical orifice airflow velocity: 50 L / h

[0091] Collision gas: Argon

[0092] Quality scan range: m / z 100-900

[0093] 4. Results Analysis

[0094] The chromatogram of celery seed extract is as follows: Figure 1 As shown, there are 18 response peaks. Specific information is shown in Table 2.

[0095] Table 2. Chromatographic-mass spectrometry characterization results of celery seed extract.

[0096] Note: The names of the substances in the table above were inferred based on retention time and known components in celery seed extract, combined with mass-to-nucleus ratio.

[0097] Based on analysis and calculations, according to peak area, the response peak in the celery seed extract is 15, i.e., [MH]. - The weight ratio of the substance with m / z = 709.18 is 1.834%.

[0098] III. Isolation and purification of celery seed extract compounds as shown in Formula I

[0099] (a) Preparation and chromatographic purification

[0100] Preparative chromatography: Column type: Waters XBridge BEH C18 preparative column, which is the same series of packing material as the analytical column above. Specifications: 10×150 mm, inner diameter 10 mm, column length 150 mm, particle size 5 μm.

[0101] Other conditions are the same as those for chromatographic analysis, and can be adjusted appropriately. The fraction monitored by UV light at 340–360 nm and whose mass spectra match [MH]=709.18 is collected separately. Other fractions are collected together. The fraction from the first analysis at 340–360 nm with mass spectra matching [MH]=709.18 is subjected to preparative chromatography again; the purity of the fraction is 99.86%.

[0102] (ii) Nuclear magnetic resonance characterization

[0103] like Figure 2 The above is the 1H NMR spectrum of the purified compound. Figure 3 The above-mentioned purified compound has a carbon NMR spectrum, where, Figure 3 (b) Figure 3 (c) are magnified views of local displacements in the ranges of 130~100ppm and 100~60ppm, respectively.

[0104] Nuclear magnetic resonance characterization revealed that the chemical structure of the fraction with a mass spectrum of 340–360 nm and [MH] = 709.18 was as follows: .

[0105] IV. Performance Testing

[0106] (I) Xanthine oxidase (XOD) inhibitory activity assay protocol

[0107] 1. Sample to be tested

[0108] Sample A to be tested: Celery seed extract prepared in the experimental method.

[0109] Sample B to be tested: A compound with the chemical structure of Formula I after chromatographic purification.

[0110] 2. Testing Methods

[0111] PBS buffer: 1400 μL, 0.01 mol / L pH 7.4 PBS buffer.

[0112] Test sample solution: 1250 μL, 0.1 mg / mL;

[0113] 0.1 U / mL XOD enzyme working solution: 100 μL

[0114] 5 mmol / L xanthine substrate working solution: 100 μL

[0115] Mix all reagents (except the substrate) thoroughly, incubate at 25°C in the dark for 10 min, then quickly add the xanthine substrate and incubate at 25°C in the dark for 5 min. Inactivate with 500 μL of 0.5 mol / L perchloric acid solution. Measure the absorbance at 290 nm.

[0116] The blank control group, containing enzyme and substrate, was replaced with an equal volume of PBS buffer to measure the normal enzymatic reaction rate. The negative control group, without XOD enzyme solution, was replaced with PBS buffer, with the remaining components identical to the sample group, to subtract spontaneous absorption interference from the substrate and the sample itself, and to eliminate systematic errors. Each experiment was repeated in triplicate, and the average value was used to calculate the xanthine oxidase inhibition rate.

[0117] XOD inhibition rate (%) = (OD value of blank group - negative OD) - (OD value of sample group - negative OD) ÷ (OD value of blank group - negative OD) × 100%

[0118] (II) Assay protocol for xanthine dehydrogenase (XDH) inhibitory activity

[0119] 1. The sample to be tested is the same as that used in the XOD experiment.

[0120] 2. Reagents

[0121] PBS buffer: 0.01 mol / L, pH=7.8

[0122] Test sample solution: 0.1 mg / mL, dissolved in PBS

[0123] XDH enzyme working solution: 0.1 U / mL, prepared with PBS, freshly prepared and used immediately.

[0124] NAD + Solution: 5 mmol / L, prepare fresh before use.

[0125] Xanthine substrate solution: 5 mmol / L (dissolved with a small amount of 0.1 mol / L NaOH, then brought to volume with PBS)

[0126] Perchloric acid termination solution: 0.5 mol / L

[0127] 3. Reaction system

[0128] PBS buffer: 1300 μL

[0129] Sample solution to be tested: 1250 μL

[0130] 0.1 U / mL XDH enzyme solution: 100 μL

[0131] 5 mmol / L NAD + 100μL

[0132] 5 mmol / L xanthine: 100 μL

[0133] 4. Operating Procedures

[0134] Add PBS, sample, XDH, and NAD+ sequentially. Pre-incubate at 25°C in the dark for 10 min. Quickly add xanthine substrate, mix well, and incubate at 25°C in the dark for 5 min. Immediately add 500 μL of 0.5 mol / L perchloric acid, mix well, and terminate the reaction. Centrifuge at 12000 rpm for 5 min, collect the supernatant, and measure the absorbance at 340 nm.

[0135] 5. Control group setup (3 replicates per group)

[0136] Control group (normal enzyme activity): PBS was used to replace the sample, containing XDH+NAD. + +Substrate → Measure the maximum reaction

[0137] Negative control group (enzyme-free): PBS replaced XDH, and the rest were the same as the control group.

[0138] XDH inhibition rate (%) = (OD value of blank group - negative OD) - (OD value of sample group - negative OD) ÷ (OD value of blank group - negative OD) × 100%

[0139] The experimental results are shown in Table 3.

[0140] Table 3. Suppression performance of XOD and XDH

[0141] (iii) Superoxide anion (O2) - •) Cleansing activity test

[0142] 1. The sample to be tested is the same as that used in the XOD experiment.

[0143] 2. Reagent preparation

[0144] PBS buffer: 0.01 mol / L, pH=7.4

[0145] Test sample solution: 0.1 mg / mL, dissolved in PBS

[0146] 50 mmol / L Tris-HCl buffer: pH=8.2 (for the pyrogallol auto-oxidation system)

[0147] 6 mmol / L pyrogallol solution: Prepared with 10 mmol / L HCl, freshly prepared and used immediately, stored away from light.

[0148] 10 mmol / L HCl solution: terminates the reaction

[0149] 3. Reaction system

[0150] Tris-HCl buffer: 1600 μL

[0151] Sample solution to be tested: 1250 μL

[0152] 6 mmol / L pyrogallol solution: 100 μL

[0153] 10 mmol / L HCl solution: 50 μL

[0154] 4. Operating Procedures

[0155] Add Tris-HCl buffer and the sample solution to be tested sequentially, mix well, and pre-incubate at 25°C in the dark for 10 min.

[0156] Add pyrogallol solution quickly, mix immediately and start timing. React at 25°C in the dark for 4 min. Immediately add 10 mmol / L HCl solution to terminate the reaction, mix well, and measure the absorbance value at a wavelength of 320 nm.

[0157] 5. Control group setup (each experiment was repeated 3 times in parallel, and the average value was taken)

[0158] Blank group: The sample solution was replaced with an equal volume of PBS buffer, and the remaining components were the same as the sample group. The absorbance of pyrogallol autoxidation was measured.

[0159] Negative control group: 10 mmol / L HCl solution was used instead of pyrogallol solution, and the remaining components were the same as the standard group.

[0160] Superoxide anion scavenging rate (%) = (OD value of blank group - negative OD) - (OD value of sample group - negative OD) ÷ (OD value of blank group - negative OD) × 100%

[0161] (iv) Protein denaturation inhibition activity test

[0162] 1. The sample to be tested is the same as that used in the XOD experiment.

[0163] 2. Reagent preparation

[0164] PBS buffer: 0.01 mol / L, pH=7.4

[0165] Test sample solution: 0.1 mg / mL, prepared with PBS

[0166] Bovine serum albumin (BSA) solution: 0.8 mg / mL, dissolved in PBS, freshly prepared and used immediately.

[0167] 10% acetic acid solution: reaction terminated

[0168] 3. Reaction system

[0169] PBS buffer: 1400 μL

[0170] Sample solution to be tested: 1250 μL

[0171] 0.8 mg / mL BSA solution: 300 μL

[0172] 4. Operating Procedures

[0173] Add PBS buffer, the sample solution, and BSA solution sequentially, mix thoroughly, and incubate at 25°C in the dark for 10 min. Then, heat in a water bath to 70°C and maintain this temperature for 10 min. Remove the test tube and cool to room temperature. Add 50 μL of 10% acetic acid solution to stabilize the system, mix well, and measure the absorbance at 278 nm using a UV spectrophotometer. Each experiment was repeated three times in parallel, and the average value was taken.

[0174] 5. Control group setup

[0175] Blank group: The same amount of PBS buffer was used to replace the sample solution, and all other components were the same.

[0176] Negative control group: PBS buffer was used instead of BSA solution, and the remaining components were the same as those in the standard group.

[0177] Protein denaturation inhibition rate (%) = (OD value of blank group - OD value of negative group) - (OD value of sample group - OD value of negative group) ÷ (OD value of blank group - OD value of negative group) × 100%

[0178] (v) Uric acid crystallization inhibition test

[0179] 1. The sample to be tested is the same as that used in the XOD experiment.

[0180] 2. Reagent preparation

[0181] PBS buffer: 0.01 mol / L, pH=7.4

[0182] Test sample solution: 0.1 mg / mL, prepared with PBS.

[0183] Uric acid stock solution: 2 mmol / L, dissolved with weakly alkaline PBS by heating, prepared fresh and used immediately, stored away from light.

[0184] Sodium chloride solution: 0.9% (simulating physiological saline environment)

[0185] 3. Reaction system (total volume 3000 μL)

[0186] PBS buffer: 1100 μL

[0187] Sample solution to be tested: 1250 μL

[0188] 0.9% NaCl solution: 200 μL

[0189] 2 mmol / L uric acid solution: 450 μL

[0190] 4. Operating Procedures

[0191] Add PBS buffer, the sample solution, 0.9% NaCl solution, and uric acid solution sequentially, mix thoroughly, and incubate at 25°C in the dark for 10 min. Then, incubate at 25°C for 60 min to induce urate crystal formation. After mixing, take a sample and measure the absorbance at 292 nm. Perform three parallel experiments per group and take the average value.

[0192] 5. Control group setup

[0193] Blank group: An equal volume of PBS buffer was used to replace the sample solution, and all other components were identical.

[0194] Negative control group: PBS buffer was used instead of uric acid solution, and the remaining components were the same as the standard group.

[0195] Uric acid crystallization inhibition rate (%) = (OD value of blank group - negative OD) - (OD value of sample group - negative OD) ÷ (OD value of blank group - negative OD) × 100%

[0196] The experimental results are shown in Table 4.

[0197] Table 4 Inhibition properties against superoxide anion, uric acid crystallization, etc.

[0198] The results above indicate that the celery seed extract compound shown in Formula I of this invention inhibits xanthine oxidase (XO) and xanthine dehydrogenase, and also scavenges superoxide anions. It possesses antioxidant and protein denaturation-inhibiting effects, which are beneficial for inhibiting uric acid crystallization and relieving gout and hyperuricemia. The celery seed extract provided by this invention has the same effects as described above.

[0199] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A celery seed extract compound, characterized in that, The chemical structural formula I of the compound extracted from celery seeds is shown below: Formula I.

2. A celery seed extract, characterized in that, The celery seed extract contains more than 0.5% by mass of the compound as described in claim 1.

3. The method for preparing celery seed extract as described in claim 2, characterized in that, The preparation method includes the following steps: (1) Mix dried celery seed powder with 50%~80% ethanol aqueous solution (v / v), adjust the pH to 4.5~5.5, and reflux at 50~65℃ for extraction. During the extraction process, control the pH to 4.5~5.

5. Concentrate the extract until there is no alcohol taste to obtain concentrated solution or concentrated extract. (2) Dilute the concentrated solution or concentrated extract with water to a solid content of 7-15% (w / v) and adjust the pH to 4.5-5.5; (3) Extracted sequentially with petroleum ether and ethyl acetate, the organic phase was removed and the aqueous phase was retained, resulting in a crude enrichment solution containing the compound as described in claim 1; (4) After the crude enrichment liquid from step (3) is concentrated under reduced pressure, it is dried at a temperature not higher than 25°C and then powdered to obtain celery seed extract.

4. The method for preparing celery seed extract according to claim 3, characterized in that, In step (1), the material-to-liquid ratio is 1:(10~20)g / mL, and the reflux extraction time is 1~3 hours; In step (1), the pH is adjusted to 4.8~5.

2. In step (2), the pH is adjusted to 4.8~5.

2.

5. The method for preparing celery seed extract according to claim 3, characterized in that, The preparation method further includes the following steps after step (3) and before step (4): the pretreated AB-8 macroporous adsorption resin adsorbs the crude enrichment liquid, and the volume ratio of the pretreated AB-8 macroporous adsorption resin to the crude enrichment liquid is 1: (1~3); the AB-8 macroporous adsorption resin is separated, and the AB-8 macroporous adsorption resin is eluted with a 20%~80% gradient ethanol aqueous solution, the ethanol volume of the 20%~80% gradient ethanol aqueous solution gradually increases with the elution sequence, and the elution fraction of the 50%~80% gradient ethanol aqueous solution is collected; Celery seed extract was obtained by concentration under reduced pressure, drying at a temperature not exceeding 25°C, and then grinding into powder.

6. The method for preparing celery seed extract according to claim 5, characterized in that, The preparation method uses AB-8 type macroporous adsorption resin column packing and elution in the steps after step (3) and before step (4).

7. The method for preparing the celery seed extract compound as described in claim 1, characterized in that, The method includes the following steps: (1) Mix dried celery seed powder with 50%~80% ethanol aqueous solution (v / v), adjust the pH to 4.5~5.5, and reflux at 50~65℃ for extraction. During the extraction process, control the pH to 4.5~5.

5. Concentrate the extract until there is no alcohol taste to obtain concentrated solution or concentrated extract. (2) Dilute the concentrated solution or concentrated extract with water to a solid content of 7-15% (w / v) and adjust the pH to 4.5-5.5; (3) Extracted sequentially with petroleum ether and ethyl acetate, the organic phase was removed and the aqueous phase was retained, resulting in a crude enrichment solution containing the compound as described in claim 1; (4) AB-8 macroporous adsorption resin pre-soaked in 95% or more ethanol was packed into a column. After loading 1 to 3 column volumes of coarse enrichment solution onto the column, it was eluted with 2.5 to 5 column volumes of water. (5) Elute the AB-8 type macroporous adsorption resin column with a gradient ethanol aqueous solution of 20%~80%. The ethanol volume of the gradient ethanol aqueous solution of 20%~80% gradually increases with the elution sequence. Collect the elution fraction of the gradient ethanol aqueous solution of 50%~80%, concentrate under reduced pressure, and dry at a temperature not higher than 25℃ to obtain celery seed extract. (6) The celery seed extract from step (5) is dissolved in 45%~55% methanol / water (v / v) to prepare a solution with a concentration of 10~50 mg / mL. After filtration through an organic filter membrane, the solution is introduced into a reversed-phase preparative chromatography-mass spectrometry instrument. The fraction with UV monitoring at 340~360 nm and mass spectra that meet the [MH]=709.18 is the fraction of the celery seed extract compound as claimed in claim 1.

8. The method for preparing the celery seed extract compound according to claim 7, characterized in that, In step (1), the material-to-liquid ratio is 1:(10~20)g / mL, and the reflux extraction time is 1~3 hours; In step (1), the pH is adjusted to 4.8~5.

2. In step (2), the pH is adjusted to 4.8~5.

2.

9. The application of the celery seed extract compound as described in claim 1 in the preparation of health products for relieving high uric acid.

10. The use of the celery seed extract as described in claim 2 in the preparation of health products for relieving high uric acid.